LOGIN  |  REGISTER
Chimerix

Exicure Announces Proposed Settlement of Securities Class Action Litigation

September 09, 2024 | Last Trade: US$11.04 5.22 89.69

CHICAGO / Sep 09, 2024 / Business Wire / Exicure, Inc. (Nasdaq: XCUR, the “Company”) announced today that it has entered into an agreement with plaintiffs to settle Colwell v. Exicure, Inc. et al., Case No. 1:21-CV-06637, a previously disclosed securities class action lawsuit pending in the United States District Court for the Northern District of Illinois (the “Court”). The settlement is subject to Court approval, and plaintiffs filed a motion for preliminary approval of the settlement with the Court on September 6, 2024.

The settlement does not constitute any admission by the Company of any liability or wrongdoing. Nonetheless, the Company believes it is beneficial to resolve the case as further litigation would be burdensome and protracted.

About Exicure

Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com.

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB